Sign In
Buy INBS
$2.44
-0.100 (-3.94%)
At Close: Jun 03, 2026
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leading innovator in non-invasive drug testing technology, today announce
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
08:30am, Tuesday, 13'th Aug 2024
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as const
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
08:30am, Thursday, 01'st Aug 2024
Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company's FDA clinical study plan.
Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia
08:30am, Wednesday, 24'th Jul 2024
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so
Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success
08:30am, Thursday, 18'th Jul 2024
NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so
Intelligent Bio Solutions Expands Presence in the UK Retail Sector with Major Account Acquisitions
08:30am, Thursday, 27'th Jun 2024
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing s
Pharmacokinetic study is key step on path to expansion into US market Pharmacokinetic study is key step on path to expansion into US market
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
08:30am, Thursday, 06'th Jun 2024
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
08:30am, Wednesday, 29'th May 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing sol
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive tes
CCC Intelligent Solutions Holdings Inc. (NYSE:CCCS) Shares Acquired by Amalgamated Bank
05:01am, Monday, 20'th May 2024
Amalgamated Bank increased its stake in shares of CCC Intelligent Solutions Holdings Inc. (NYSE:CCCS – Free Report) by 34.7% during the 4th quarter, according to its most recent filing with the
Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event
08:30am, Friday, 17'th May 2024
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing sol
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
08:30am, Wednesday, 08'th May 2024
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024
